SCHEMBL24096486

SCHEMBL24096486

Nc1ncnc2c1c(I)nn2-c1ccncc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 3/20 0.50
▸ EGFR P00533 2/20 0.50
▸ KDM4E B2RXH2 2/20 0.45
▸ DYRK3 O43781 2/20 0.44
▸ CDK1 P06493 2/20 0.44
▸ ROS1 P08922 2/20 0.44
▸ RPS6KB1 P23443 2/20 0.44
▸ CDK2 P24941 2/20 0.44
▸ CSNK1A1 P48729 2/20 0.44
▸ CSNK1D P48730 2/20 0.44
▸ CLK2 P49760 2/20 0.44
▸ IRAK1 P51617 2/20 0.44
▸ CDK5 Q00535 2/20 0.44
▸ DYRK1A Q13627 2/20 0.44
▸ NTRK3 Q16288 2/20 0.44
▸ SLK Q9H2G2 2/20 0.44
▸ CLK4 Q9HAZ1 2/20 0.44
▸ CDC7 O00311 1/20 0.44
▸ PLK4 O00444 1/20 0.44
▸ JAK2 O60674 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24096482 0.83 PIK3CD (0.55) SRCEGFRKDM4EGSK3BPIK3CD
SCHEMBL4825966 0.82 SRC (0.43) SRCEGFRKDM4EDYRK3CDK1
SCHEMBL13201536 0.81 SRC (0.47) SRCEGFRKDM4EDYRK3CDK1
SCHEMBL4828333 0.81 SRC (0.47) SRCEGFRKDM4EDYRK3CDK1
SCHEMBL2969443 0.80 SRC (0.46) SRCEGFRKDM4EDYRK3CDK1
SCHEMBL5803258 0.78 XDH (0.58) SRCEGFRKDM4EDYRK3CDK1
SCHEMBL27587387 0.77 SRC (0.45) SRCEGFRKDM4EDYRK3CDK1
SCHEMBL401337 0.74 SRC (0.45) SRCEGFRKDM4EDYRK3CDK1
SCHEMBL29484487 0.73 SRC (0.50) SRCEGFRDYRK3CDK1RPS6KB1
SCHEMBL16236616 0.73 SRC (0.50) SRCEGFRDYRK3CDK1RPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230203045-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2023-06-29 — — US disclosed
US-20230203045-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2023-06-29 — — US disclosed
US-20230203045-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2023-06-29 — — US disclosed
CN-116075513-A Inhibitors of NEK7 kinase 哈利亚治疗公司 2023-05-05 — — CN disclosed
EP-4161933-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2023-04-12 — — EP disclosed
WO-2021252488-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-16 — — WO disclosed
WO-2021252488-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203045-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 SRC 651/4885EGFR 4664/4885KDM4E 1783/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 SRC 3388/4885EGFR 4872/4885KDM4E 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback